Is CRSP or CTNM more undervalued in 2026?

CirclFi compares CRISPR Therapeutics AG (CRSP) and Contineum Therapeutics, Inc. (CTNM) using 13 institutional-grade valuation models. CRSP has a Quality of Company score of 6.2/10 while CTNM scores 4.6/10.

Which is a better buy — CRSP or CTNM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CRSP and CTNM valuations compare?

CRSP at $56.38 and CTNM at $13.31 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CRSP vs CTNM Valuation Comparison 2026 — Intrinsic Value Analysis

CRSP

Biotechnology

CRISPR Therapeutics AG

Quality

6.2

out of 10

Value Trap

SAFE

Price

$56.38

Last close

Models

12/13

Active

CTNM

Biotechnology

Contineum Therapeutics, Inc.

Quality

4.6

out of 10

Value Trap

SAFE

Price

$13.31

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	CRSP Fair Value	CRSP Upside	CTNM Fair Value	CTNM Upside
Bayesian DCF	Intrinsic	$10.94	-80.6%	$0.26	-98.2%
Earnings Power Value	Intrinsic	$27.66	-43.3%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$8.56	-84.8%	$3.43	-74.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRSP vs CTNM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRSP vs CTNM — Which Stock Is More Undervalued?

CRSP scores higher with a 6.2/10 quality rating vs CTNM's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing CRISPR Therapeutics AG (CRSP) and Contineum Therapeutics, Inc. (CTNM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRSP currently trades at $56.38 with a QOC of 6.2/10, while CTNM trades at $13.31 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).